.jpg?#)
FDA approves Soleno’s rare disease drug for Prader-Willi syndrome
The FDA on Wednesday approved Soleno Therapeutics' new drug designed to treat the worst symptom of a debilitating rare disease known as Prader-Willi syndrome. Regulators approved diazoxide choline (often shortened to DCCR) to treat insatiable ...
The FDA on Wednesday approved Soleno Therapeutics' new drug designed to treat the worst symptom of a debilitating rare disease known as Prader-Willi syndrome.
Regulators approved diazoxide choline (often shortened to DCCR) to treat insatiable ...
